Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study

Published 2015 View Full Article

Authors

Keywords

Journal

LANCET ONCOLOGY

Volume 16, Issue 9, Pages 1025-1036

Publisher

Elsevier BV

Online

2015-07-31

DOI

10.1016/s1470-2045(15)00201-6

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started